Invest now

Aarti Pharmalabs share price

High risk
  • 47%Low risk
  • 47%Moderate risk
  • 47%Balanced risk
  • 47%High risk
  • 47%Extreme risk
Analyse on
AI
  • ₹826.90(0.23%)
    September 11, 2026 15:26:23 PM IST
    • NSE
    • BSE
  • Vol : 289.21 K (NSE + BSE)
    Last 20 day avg : 461.60 K
Aarti Pharmalabs is trading 0.23% upper at Rs 826.90 as compared to its last closing price. Aarti Pharmalabs has been trading in the price range of 833.10 & 814.50. Aarti Pharmalabs has given 9.75% in this year & -4.88% in the last 5 days. Aarti Pharmalabs has TTM P/E ratio 30.63 as compared to the sector P/E of 37.04.The company posted a net profit of 76.14 Crores in its last quarter.Listed peers of Aarti Pharmalabs include Sun Pharmaceutical Industries (-1.18%), Divi's Laboratories (-0.84%), Torrent Pharmaceuticals (0.95%).The Mutual Fund holding in Aarti Pharmalabs was at 0.79% in 30 Jun 2026. The MF holding has decreased from the last quarter. The FII holding in Aarti Pharmalabs was at 8.17% in 30 Jun 2026. The FII holding has decreased from the last quarter.
  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Loading...
Screen on
Try Now
Key Metrics

Updated on 13 Sep 2026, 08:11 AM IST

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.98
    Medium volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.36
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.42
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -11.08
    Indicates undervaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
Price range
Day Range
Lowest
814.50
Highest
833.10
52 week range
Lowest
583.85
Highest
946.45
Aarti Pharmalabs News
Aarti Pharmalabs Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries		1,842.00-1.184,41,947.0938.405.550.830.47
Divi's Laboratories		9,326.00-0.842,47,576.0073.3211.480.410.03
Torrent Pharmaceuticals		4,975.000.951,89,226.2472.7319.220.80141.16
Cipla		1,365.00-1.091,10,272.6827.573.330.921.11
Zydus Lifesciences		1,119.500.131,11,670.5621.194.240.0914.22
Mutual Fund Ownership
View all
Union Active Momentum Fund Regular Growth
NA
  • Amount Invested (Cr.) 8.29
  • % of AUM 1.86
Samco Active Momentum Fund Regular Growth
NA
  • Amount Invested (Cr.) 6.56
  • % of AUM 0.76
Motilal Oswal Nifty Microcap 250 Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 14.22
  • % of AUM 0.60
Bandhan BSE Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.07
  • % of AUM 0.36
Samco Multi Cap Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.23
  • % of AUM 0.33
Aarti Pharmalabs Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-08-07Quarterly Results
2026-05-25Audited Results & Final Dividend
2026-05-18Audited Results & Final Dividend
2026-02-09Quarterly Results & Interim Dividend
2025-11-09Quarterly Results
About the company Aarti Pharmalabs
  • IndustryBiotechnology & Drugs
  • ISININE0LRU01027
  • BSE Code543748
  • NSE CodeAARTIPHARM
Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. The Company's products are exported to key regulated markets such as the United States (US), the European Union, and Japan.
  • Management Info
  • Rashesh GogriChairman of the Board
  • Hetal GalaVice Chairperson of the Board, Managing Director
  • Rakeshwar BandichhorChief Scientific Officer - Research and Development
  • Jeevan MondkarCompany Secretary and Compliance Officer
Aarti Pharmalabs Share Price FAQs

Aarti Pharmalabs is trading at 826.90 as on Fri Sep 11 2026 09:56:23. This is 0.23% upper as compared to its previous closing price of 825.00.

The market capitalization of Aarti Pharmalabs is 7491.50 Cr as on Fri Sep 11 2026 09:56:23.

The 52 wk high for Aarti Pharmalabs is 946.45 whereas the 52 wk low is 583.85

Aarti Pharmalabs can be analyzed on the following key metrics -

  • TTM P/E: 30.63
  • Sector P/E: 37.04
  • Dividend Yield: 0.42%
  • D/E ratio: -

Aarti Pharmalabs reported a net profit of 174.71 Cr in 2026.

The Mutual Fund Shareholding was 0.79% at the end of 30 Jun 2026.

Quick Links
EQUITY QUICK LINKS
Aarti Pharmalabs QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Home/Market/Market Stats/  Aarti Pharmalabs share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.